E

    Eterna Therapeutics Inc (ERNA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.57
    +0.00 (+0.00%)

    Market Cap: $5.33M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    52%(12/23)
    Avg Surprise
    -352.22%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-3.84
    Range$-3.84 - $-3.84
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$0.00+100.0%
    60d ago$-3.84+0.0%
    30d ago$-3.84+0.0%
    7d ago$-3.84+0.0%
    Current$-3.84
    Revenue Consensus
    $0
    Range$0 - $0
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Sep 26EST
    		-$-3.84---
    Jun 26
    		$-3.40$-3.30-3.03%Miss-457.4%
    Mar 26
    		$-6.95$-1.95-256.41%Miss-200.9%
    Dec 25
    		$-4.81N/AN/ABeat-3104.3%
    Sep 25
    		$-0.15$0.00N/AMiss+100.0%
    Jun 25
    		$-0.61$0.00N/AMiss+99.8%
    Mar 25
    		$-2.31$0.00N/AMiss+99.5%
    Dec 24
    		$-0.15$0.00N/AMiss+100.0%
    Sep 24
    		$-1844.09$0.00N/ABeat-178331.1%
    Jun 24
    		$-383.80$0.00N/ABeat-44968.5%
    Mar 24
    		$-460.74$0.00N/ABeat-37056.8%
    Dec 23
    		$-427.06$0.00N/ABeat-34340.0%
    Sep 23
    		$-1.03N/AN/ABeat+99.9%
    Jun 23
    		$-0.85N/AN/ABeat+99.8%
    Mar 23
    		$-1.24$-0.14-785.71%Miss+61.3%
    Dec 22
    		$-1.24$-0.14-785.71%Miss+61.3%
    Sep 22
    		$-933.75$-825.00-13.18%Miss+92.7%
    Jun 22
    		$-450.00N/A+53.85%Beat-187400.0%
    Mar 22
    		$-3.20N/A+99.66%Beat-16100.0%
    Dec 21
    		$-3.20N/A+99.66%Beat-3300.0%
    Sep 21
    		$-12749.99$-600.00-2025.00%Beat-63750050.0%
    Jun 21
    		$-0.24N/AN/ABeat-1300.0%
    Mar 21
    		$0.02N/AN/ABeat+0.0%
    Dec 20
    		$0.10N/AN/ABeat+122.2%
    Sep 20
    		$0.02N/AN/ABeat+116.7%
    Jun 20
    		$0.02N/AN/ABeat+166.7%
    Mar 20
    		$0.02N/AN/ABeat+118.2%
    Dec 19
    		$-0.45$0.01-4600.00%Miss-110.2%
    Sep 19
    		$-0.12$-0.03-300.00%Miss-103.8%
    Jun 19
    		$-0.03$-0.03+0.00%Beat+98.5%
    Mar 19
    		$-0.11$0.20-155.00%Miss+98.3%
    Dec 18
    		$4.40$6.00-26.67%Miss+144.0%
    Sep 18
    		$3.20$-1.60+300.00%Beat+214.3%
    Jun 18
    		$-2.00N/A+78.26%Beat+28.6%
    Mar 18
    		$-6.40$-10.80+40.74%Beat-300.0%
    Dec 17
    		$-10.00$-5.60-78.57%Miss-13.6%
    Sep 17
    		$-2.80N/A+66.67%Beat+77.4%
    Jun 17
    		$-2.80N/A+80.00%Beat-
    Mar 17
    		$-1.60N/A+89.74%Beat-
    Dec 16
    		$-8.80$-7.60-15.79%Miss-
    Sep 16
    		$-12.40$-19.20+35.42%Beat-

    Key Metrics

    Valuation
    P/E Ratio-0.30EV/EBITDA-0.29x
    Price/FCF-0.61xFCF Yield-164.22%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-320.70%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage17.17x
    Current Ratio2.01xQuick Ratio2.01x
    Trading Statistics
    Beta2.56Avg Volume42.10K
    52-Week High$48.0052-Week Low$3.18

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.68
    SMA 20$4.49
    SMA 50$5.10
    SMA 200$13.74
    EMA 10$4.64
    EMA 20$4.60
    EMA 50$5.21
    EMA 200$15.72

    MACD

    Line: -0.06Signal: -0.15Hist: 0.10

    ADX

    ADX: 18.2+DI: 25.6-DI: 16.0

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down20.0
    PSAR$4.52

    Bollinger Bands

    Upper Band$5.05
    Lower Band$3.94
    %B Position2465%(Upper)
    Band Width0.57

    RSI (14-Day)

    Neutral
    47.8

    Momentum Oscillators

    Stoch %K40.6
    Stoch %D48.1
    Williams %R-63.1
    ROC (10d)12.6%
    Momentum0.51
    CCI (20d)31.2
    MFI (14d)63.0

    Volatility Measures

    ATR (14d)$0.49(10.7%)
    StdDev (20d)0.28
    Hist Vol119.7%(High)

    Volume Flow

    VWAP$4.62
    OBV350.2M
    AD Line228.5B
    CMF (20d)-0.105

    Volume Metrics

    Avg Vol (20d)42.1K
    Vol Ratio0.2x(Low)
    VWMA (20d)$4.49

    Pivot Points

    R3$5.28
    R2$5.14
    R1$4.85
    Pivot Point$4.71
    S1$4.42
    S2$4.28
    S3$3.99

    Advanced Oscillators

    TSI-3.33
    Ultimate Osc35.4
    KST18.34

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$1,000$487,000$47,000$47,000$17,000$51,000
    Cost of Revenue$0$0$69,000$0$0$0$-541,000$-60,000$95,000$61,000$66,000$120,000
    Gross Profit$0$0$-69,000$0$0$0$1,000$547,000$-48,000$-14,000$-49,000$-69,000
    Operating Expenses$4.10M$5.59M$2.10M$1.99M$2.50M$2.73M$2.70M$2.81M$4.88M$5.77M$5.72M$5.44M
    R&D$2.79M$1.92M$676,000$1.03M$1.14M$1.31M$1.16M$1.00M$987,000$1.46M$1.36M$1.39M
    SG&A$1.31M$1.63M$1.42M$958,000$1.36M$1.42M$1.54M$3.38M$3.90M$4.32M$4.36M$4.05M
    Operating Income$-4,104,000$-5,590,000$-2,095,000$-1,993,000$-2,501,000$-2,730,000$-2,697,000$-2,259,000$-4,931,000$-5,787,000$-5,765,000$-5,505,000
    Interest Income$55,000$44,000$20,000$31,000$0$5,000$-3,234,000$-1,686,000$-797,000$-786,000$-388,000$-113,000
    Interest Expense$-41,000$0$0$-734,000$0$5.46M$3.05M$22.44M$595,000$856,000$392,000$0
    Income Before Tax$-4,009,000$-5,546,000$-1,565,000$-1,234,000$-3,136,000$-8,194,000$-5,748,000$-26,592,000$-5,526,000$-6,643,000$-6,157,000$-5,599,000
    Income Tax Expense$0$-40,000$-62,000$6,000$3,000$8,000$11,000$12,000$3,000$4,000$-4,000$-8,000
    Net Income$-4,009,000$-5,506,000$-1,503,000$-1,240,000$-3,139,000$-8,202,000$-5,759,000$-26,604,000$-5,529,000$-6,647,000$-6,153,000$-5,591,000
    EBITDA$-4,060,000$-5,504,000$-1,547,000$-1,929,000$-3,081,000$-8,130,000$665,000$-786,000$-3,677,000$-4,871,000$-5,037,000$-4,917,000
    EBIT$-4,104,000$-5,590,000$-1,616,000$-1,999,000$-3,136,000$-8,199,000$-2,514,000$-2,466,000$-4,729,000$-5,857,000$-5,769,000$-5,486,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ERNA

    News

    Price to sales forward of Ernexa Therapeutics Inc. – NASDAQ:ERNAW

    The article provides financial information for Ernexa Therapeutics Inc. (NASDAQ: ERNAW), specifically focusing on its price-to-sales forward ratio. It notes that the market for ERNAW was closed with no trades. The content is presented as a financial data point from TradingView.

    TradingView•8/25/26•
    Neutral

    ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know

    Ernexa Therapeutics (ERNA) stock has surged 140.2% in a month following promising preclinical results for its lead cell therapy candidate, ERNA-101. The therapy, when combined with PD-1 blockade, achieved complete tumor clearance and 100% long-term survival in ovarian cancer models, by remodeling the tumor microenvironment. These findings are significant for advancing ERNA-101 toward clinical studies for advanced ovarian cancer, an area with high unmet medical needs.

    qz.com•8/18/26•
    Bullish

    Ernexa appoints David Polinsky to board ahead of IND filing

    Ernexa Therapeutics has appointed David Polinsky to its Board of Directors in anticipation of submitting an Investigational New Drug (IND) application for ERNA-101 in Q3 2026 and commencing a Phase 1 clinical study in Q4 2026. Polinsky brings over 25 years of biotechnology experience, including capital markets, M&A, and corporate governance, currently serving as CFO of Rafael Holdings. His expertise will be crucial as Ernexa advances its cell therapy for advanced cancer and autoimmune diseases, with ERNA-101 initially targeting ovarian cancer.

    Investing.com•8/11/26•
    Bullish

    Biotech veteran with 25 years’ experience joins Ernexa board

    Ernexa Therapeutics has appointed David Polinsky, a veteran biotech executive with over 25 years of experience, to its Board of Directors. This move comes as the company prepares to submit an Investigational New Drug (IND) application for its lead cell therapy program, ERNA-101, in Q3 2026 and initiate its first Phase 1 clinical study in Q4 2026. Polinsky's expertise in oncology, capital markets, M&A, and corporate governance is expected to strengthen Ernexa's leadership during its transition to a clinical-stage company.

    Stock Titan•8/10/26•
    Bullish

    Ernexa Therapeutics Strengthens Board with Veteran Biotech Executive David Polinsky as Company Approaches Clinical Stage

    Ernexa Therapeutics has appointed David Polinsky, a veteran biotech executive, to its Board of Directors. This appointment strengthens the company's leadership as it prepares to submit an Investigational New Drug (IND) application for its lead program, ERNA-101, in Q3 2026 and initiate a Phase 1 clinical study in Q4 2026. Polinsky brings over 25 years of experience in oncology, capital markets, M&A, and corporate governance to Ernexa as it transitions into a clinical-stage company.

    GlobeNewswire•8/10/26•
    Bullish

    Frequently Asked Questions About ERNA

    Does ERNA pay dividends?
    Eterna Therapeutics Inc (ERNA) does not currently pay a regular dividend.
    What is ERNA's market cap?
    Eterna Therapeutics Inc (ERNA) has a market capitalization of $5.33M with a current stock price of $4.57.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In